EP2267009A3 - Neurotoxines recombinantes activables - Google Patents
Neurotoxines recombinantes activables Download PDFInfo
- Publication number
- EP2267009A3 EP2267009A3 EP10185370A EP10185370A EP2267009A3 EP 2267009 A3 EP2267009 A3 EP 2267009A3 EP 10185370 A EP10185370 A EP 10185370A EP 10185370 A EP10185370 A EP 10185370A EP 2267009 A3 EP2267009 A3 EP 2267009A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- recombinant neurotoxins
- activatable recombinant
- polypeptides
- nucleic acids
- neurotoxins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002581 neurotoxin Substances 0.000 title abstract 2
- 231100000618 neurotoxin Toxicity 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15071099P | 1999-08-25 | 1999-08-25 | |
EP06002253.0A EP1700918B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP00964920A EP1206554B2 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines de recombinaison activables |
Related Parent Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00964920A Division EP1206554B2 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines de recombinaison activables |
EP06002253.0A Division EP1700918B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP06002253.0A Division-Into EP1700918B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP00964920.3 Division | 2000-08-25 | ||
EP06002253.0 Division | 2006-02-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2267009A2 EP2267009A2 (fr) | 2010-12-29 |
EP2267009A3 true EP2267009A3 (fr) | 2011-04-20 |
EP2267009B1 EP2267009B1 (fr) | 2014-10-29 |
Family
ID=22535688
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10185389.3A Expired - Lifetime EP2267010B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP10185391A Withdrawn EP2264052A3 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP10185355.4A Expired - Lifetime EP2267008B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP06002253.0A Expired - Lifetime EP1700918B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP00964920A Expired - Lifetime EP1206554B2 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines de recombinaison activables |
EP10185370.3A Expired - Lifetime EP2267009B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10185389.3A Expired - Lifetime EP2267010B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP10185391A Withdrawn EP2264052A3 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP10185355.4A Expired - Lifetime EP2267008B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP06002253.0A Expired - Lifetime EP1700918B1 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines recombinantes activables |
EP00964920A Expired - Lifetime EP1206554B2 (fr) | 1999-08-25 | 2000-08-25 | Neurotoxines de recombinaison activables |
Country Status (13)
Country | Link |
---|---|
US (16) | US7132259B1 (fr) |
EP (6) | EP2267010B1 (fr) |
JP (1) | JP2003507073A (fr) |
KR (1) | KR100876060B1 (fr) |
CN (1) | CN1214114C (fr) |
AT (1) | ATE348178T1 (fr) |
AU (1) | AU777556B2 (fr) |
BR (1) | BR0012759A (fr) |
CA (1) | CA2380457A1 (fr) |
DE (1) | DE60032367T3 (fr) |
ES (1) | ES2277854T5 (fr) |
HK (1) | HK1046020B (fr) |
WO (1) | WO2001014570A1 (fr) |
Families Citing this family (209)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US8012491B2 (en) | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
EP2267010B1 (fr) * | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Neurotoxines recombinantes activables |
US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
GB0111146D0 (en) * | 2001-05-04 | 2001-06-27 | Imp College Innovations Ltd | Methods |
US7332567B2 (en) * | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US8022172B2 (en) * | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
US7374896B2 (en) * | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
US7022329B2 (en) * | 2002-02-25 | 2006-04-04 | Allergan, Inc. | Method for treating neurogenic inflammation pain with botulinum toxin and substance P components |
NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
WO2005056752A2 (fr) | 2003-10-24 | 2005-06-23 | Gencia Corporation | Procedes et compositions permettant de distribuer des polynucleotides |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
AU2005279741B2 (en) * | 2004-09-01 | 2011-10-06 | Allergan, Inc. | Degradable clostridial toxins |
DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
US7785606B2 (en) * | 2004-11-22 | 2010-08-31 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
DE102005002978B4 (de) * | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
JP2008532549A (ja) | 2005-03-15 | 2008-08-21 | アラーガン、インコーポレイテッド | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 |
DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
CA2610103A1 (fr) * | 2005-09-19 | 2007-03-19 | Allergan, Inc. | Toxines clostridiales activables par toxines clostridiales |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
CA2601537A1 (fr) | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Toxines clostridiales modifiees presentant des capacites de ciblage modifiees destinees a des cellules cibles de toxines clostridiales |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
AU2007272515B2 (en) * | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
WO2008008805A2 (fr) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes |
EP2505592A1 (fr) | 2006-07-11 | 2012-10-03 | Allergan, Inc. | Toxines clostridiales modifiées à capacité de translocation améliorée et activité de ciblage augmentée |
EP2046375B1 (fr) * | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Procédés et compositions permettant une activation sélective de protoxines par un ciblage combinatoire |
WO2009055350A1 (fr) * | 2007-10-23 | 2009-04-30 | Allergan, Inc. | Procédés de traitement d'une inflammation neurogénique chronique à l'aide de toxines clostridiennes modifiées |
BRPI0817775A2 (pt) * | 2007-10-23 | 2015-03-24 | Allergan Inc | Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas |
ES2524312T3 (es) | 2008-03-14 | 2014-12-05 | Allergan, Inc. | Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica |
KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 |
KR101642363B1 (ko) * | 2008-06-12 | 2016-07-25 | 입센 바이오이노베이션 리미티드 | 신경내분비계 질환의 억제 |
US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
WO2010016901A1 (fr) * | 2008-08-05 | 2010-02-11 | Solstice Neurosciences, Inc. | Compositions d'holotoxine botulinique activée de type b (150 kd) |
WO2010016895A1 (fr) * | 2008-08-05 | 2010-02-11 | Solstice Neurosciences, Inc. | Compositions de toxine botulinique activée de type b |
WO2010051039A1 (fr) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions de toxine botulinique activée de type b |
US20100112006A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type B (150 kD) |
KR20110106346A (ko) | 2008-12-10 | 2011-09-28 | 알러간, 인코포레이티드 | 클로스트리디움 독소 약제학적 조성물 |
EP2202518A1 (fr) | 2008-12-19 | 2010-06-30 | Merz Pharma GmbH & Co.KGaA | Analyse in vivo pour quantifier l'activité de neurotoxine clostridienne |
US9492505B2 (en) | 2009-01-21 | 2016-11-15 | University Of Florida Research Foundation, Inc. | Satiation peptide administration |
EP2218783A1 (fr) | 2009-02-05 | 2010-08-18 | Merz Pharma GmbH & Co. KGaA | Nouveau procédé pour la fabrication de neurotoxines |
GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
KR102017327B1 (ko) | 2009-03-13 | 2019-09-03 | 알러간, 인코포레이티드 | 면역 기반 보툴리눔 독소 혈청형 a 활성 검정에 유용한 세포 |
SG174353A1 (en) | 2009-03-13 | 2011-11-28 | Allergan Inc | Immuno-based retargeted endopeptidase activity assays |
MX2011011045A (es) * | 2009-04-27 | 2011-11-04 | Merz Pharma Gmbh & Co Kgaa | Medios y metodos para determinacion de cantidad de polipeptido de neurotoxina y de sus actividades cataliticas y proteoliticas. |
KR20120062772A (ko) * | 2009-08-14 | 2012-06-14 | 알러간, 인코포레이티드 | 글루카곤 유사 호르몬 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법 |
WO2011020052A1 (fr) * | 2009-08-14 | 2011-02-17 | Allergan, Inc. | Méthodes de traitement du cancer au moyen d'endopeptidases dotées de nouvelles cibles grâce à des opioïdes |
CA2771289A1 (fr) * | 2009-08-14 | 2011-02-17 | Allergan, Inc. | Methodes de traitement du cancer au moyen d'endopeptidases dotees de nouvelles cibles grace a de la galanine |
CA2776778A1 (fr) * | 2009-10-01 | 2011-04-07 | Nikos Tsopanoglou | Peptides de parstatine |
EP2483666A1 (fr) | 2009-10-02 | 2012-08-08 | Allergan, Inc. | Procédé pour déterminer des changements in vitro dans un environnement protéique |
RU2012129557A (ru) | 2009-12-16 | 2014-01-27 | Аллерган, Инк. | МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ |
US9310386B2 (en) | 2010-01-22 | 2016-04-12 | Merz Pharma Gmbh & Co. Kgaa | In vitro assay for quantifying clostridial neurotoxin activity |
US8980284B2 (en) * | 2010-01-25 | 2015-03-17 | New York University | Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
CN102822196B (zh) | 2010-01-25 | 2014-12-17 | 阿勒根公司 | 将单链蛋白质细胞内转化成它们的双链形式的方法 |
US8989186B2 (en) | 2010-06-08 | 2015-03-24 | Brocade Communication Systems, Inc. | Virtual port grouping for virtual cluster switching |
US8867552B2 (en) | 2010-05-03 | 2014-10-21 | Brocade Communications Systems, Inc. | Virtual cluster switching |
US9461840B2 (en) | 2010-06-02 | 2016-10-04 | Brocade Communications Systems, Inc. | Port profile management for virtual cluster switching |
US9270486B2 (en) | 2010-06-07 | 2016-02-23 | Brocade Communications Systems, Inc. | Name services for virtual cluster switching |
US9001824B2 (en) | 2010-05-18 | 2015-04-07 | Brocade Communication Systems, Inc. | Fabric formation for virtual cluster switching |
US9716672B2 (en) | 2010-05-28 | 2017-07-25 | Brocade Communications Systems, Inc. | Distributed configuration management for virtual cluster switching |
SG10201506567UA (en) | 2010-05-20 | 2015-10-29 | Allergan Inc | Degradable Clostridial Toxins |
US9628293B2 (en) | 2010-06-08 | 2017-04-18 | Brocade Communications Systems, Inc. | Network layer multicasting in trill networks |
US9246703B2 (en) | 2010-06-08 | 2016-01-26 | Brocade Communications Systems, Inc. | Remote port mirroring |
US9608833B2 (en) | 2010-06-08 | 2017-03-28 | Brocade Communications Systems, Inc. | Supporting multiple multicast trees in trill networks |
US9807031B2 (en) | 2010-07-16 | 2017-10-31 | Brocade Communications Systems, Inc. | System and method for network configuration |
WO2012020057A1 (fr) * | 2010-08-11 | 2012-02-16 | Merz Pharma Gmbh & Co. Kgaa | Fabrication sélective de polypeptides de neurotoxine recombinants |
WO2012048246A1 (fr) | 2010-10-08 | 2012-04-12 | Allergan, Inc. | Réduction d'une réponse d'un anticorps contre la neurotoxine botulique et des variants de celle-ci |
US20130261062A1 (en) | 2010-10-14 | 2013-10-03 | Allergan, Inc. | Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
US20120207734A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases |
US20120207743A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases |
US20120207742A1 (en) | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Treatments Using PSMA Ligand Endopeptidases |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
US9270572B2 (en) | 2011-05-02 | 2016-02-23 | Brocade Communications Systems Inc. | Layer-3 support in TRILL networks |
US9764009B2 (en) | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
US9401861B2 (en) | 2011-06-28 | 2016-07-26 | Brocade Communications Systems, Inc. | Scalable MAC address distribution in an Ethernet fabric switch |
US8948056B2 (en) | 2011-06-28 | 2015-02-03 | Brocade Communication Systems, Inc. | Spanning-tree based loop detection for an ethernet fabric switch |
US9407533B2 (en) | 2011-06-28 | 2016-08-02 | Brocade Communications Systems, Inc. | Multicast in a trill network |
US8885641B2 (en) | 2011-06-30 | 2014-11-11 | Brocade Communication Systems, Inc. | Efficient trill forwarding |
US9736085B2 (en) | 2011-08-29 | 2017-08-15 | Brocade Communications Systems, Inc. | End-to end lossless Ethernet in Ethernet fabric |
US9699117B2 (en) | 2011-11-08 | 2017-07-04 | Brocade Communications Systems, Inc. | Integrated fibre channel support in an ethernet fabric switch |
US9450870B2 (en) | 2011-11-10 | 2016-09-20 | Brocade Communications Systems, Inc. | System and method for flow management in software-defined networks |
US20140377248A1 (en) | 2011-12-23 | 2014-12-25 | Merz Pharma Gmbh & Co. Kgaa | Method for the manufacturing of di-chain proteins for use in humans |
US20130171122A1 (en) | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
WO2013102088A2 (fr) | 2011-12-31 | 2013-07-04 | Allergan, Inc. | Dosage cellulaire extrêmement sensible pour détecter la présence d'une neurotoxine active botulique de sérotype a |
US8995272B2 (en) | 2012-01-26 | 2015-03-31 | Brocade Communication Systems, Inc. | Link aggregation in software-defined networks |
US9742693B2 (en) | 2012-02-27 | 2017-08-22 | Brocade Communications Systems, Inc. | Dynamic service insertion in a fabric switch |
US9154416B2 (en) | 2012-03-22 | 2015-10-06 | Brocade Communications Systems, Inc. | Overlay tunnel in a fabric switch |
US9374301B2 (en) | 2012-05-18 | 2016-06-21 | Brocade Communications Systems, Inc. | Network feedback in software-defined networks |
US10277464B2 (en) | 2012-05-22 | 2019-04-30 | Arris Enterprises Llc | Client auto-configuration in a multi-switch link aggregation |
US10454760B2 (en) | 2012-05-23 | 2019-10-22 | Avago Technologies International Sales Pte. Limited | Layer-3 overlay gateways |
US9602430B2 (en) | 2012-08-21 | 2017-03-21 | Brocade Communications Systems, Inc. | Global VLANs for fabric switches |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
CA2889833A1 (fr) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions et procedes pour le traitement sur de la rhinite |
GB201219602D0 (en) | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
US9401872B2 (en) | 2012-11-16 | 2016-07-26 | Brocade Communications Systems, Inc. | Virtual link aggregations across multiple fabric switches |
RU2673910C2 (ru) | 2012-11-21 | 2018-12-03 | Ипсен Байоинновейшн Лимитед | Способ производства протеолитически процессированного полипептида |
WO2014100019A1 (fr) | 2012-12-18 | 2014-06-26 | Allergan, Inc. | Traitement prophylactique de la récurrence de l'herpès |
US9548926B2 (en) | 2013-01-11 | 2017-01-17 | Brocade Communications Systems, Inc. | Multicast traffic load balancing over virtual link aggregation |
US9350680B2 (en) | 2013-01-11 | 2016-05-24 | Brocade Communications Systems, Inc. | Protection switching over a virtual link aggregation |
US9413691B2 (en) | 2013-01-11 | 2016-08-09 | Brocade Communications Systems, Inc. | MAC address synchronization in a fabric switch |
US9565113B2 (en) | 2013-01-15 | 2017-02-07 | Brocade Communications Systems, Inc. | Adaptive link aggregation and virtual link aggregation |
WO2014117148A1 (fr) | 2013-01-28 | 2014-07-31 | New York University | Méthodes de traitement au moyen de dérivés atoxiques de neurotoxine |
US9565099B2 (en) | 2013-03-01 | 2017-02-07 | Brocade Communications Systems, Inc. | Spanning tree in fabric switches |
US9401818B2 (en) | 2013-03-15 | 2016-07-26 | Brocade Communications Systems, Inc. | Scalable gateways for a fabric switch |
US9699001B2 (en) | 2013-06-10 | 2017-07-04 | Brocade Communications Systems, Inc. | Scalable and segregated network virtualization |
US9565028B2 (en) | 2013-06-10 | 2017-02-07 | Brocade Communications Systems, Inc. | Ingress switch multicast distribution in a fabric switch |
CN105339790B (zh) | 2013-06-28 | 2018-04-17 | 莫茨制药有限及两合公司 | 用于确定神经毒素多肽在细胞中的生物活性的工具和方法 |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US9806949B2 (en) | 2013-09-06 | 2017-10-31 | Brocade Communications Systems, Inc. | Transparent interconnection of Ethernet fabric switches |
US9912612B2 (en) | 2013-10-28 | 2018-03-06 | Brocade Communications Systems LLC | Extended ethernet fabric switches |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
US9548873B2 (en) | 2014-02-10 | 2017-01-17 | Brocade Communications Systems, Inc. | Virtual extensible LAN tunnel keepalives |
US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
US10581758B2 (en) | 2014-03-19 | 2020-03-03 | Avago Technologies International Sales Pte. Limited | Distributed hot standby links for vLAG |
US10476698B2 (en) | 2014-03-20 | 2019-11-12 | Avago Technologies International Sales Pte. Limited | Redundent virtual link aggregation group |
US10063473B2 (en) | 2014-04-30 | 2018-08-28 | Brocade Communications Systems LLC | Method and system for facilitating switch virtualization in a network of interconnected switches |
CA2947006A1 (fr) | 2014-04-30 | 2015-11-05 | Eric A. Forssen | Formulations d'agents biologiques pour instillation intravesicale |
US9800471B2 (en) | 2014-05-13 | 2017-10-24 | Brocade Communications Systems, Inc. | Network extension groups of global VLANs in a fabric switch |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US10616108B2 (en) | 2014-07-29 | 2020-04-07 | Avago Technologies International Sales Pte. Limited | Scalable MAC address virtualization |
US9544219B2 (en) | 2014-07-31 | 2017-01-10 | Brocade Communications Systems, Inc. | Global VLAN services |
KR20220048046A (ko) | 2014-07-31 | 2022-04-19 | 알러간, 인코포레이티드 | 방광내 주입을 위한 생물학 제형 |
US9807007B2 (en) | 2014-08-11 | 2017-10-31 | Brocade Communications Systems, Inc. | Progressive MAC address learning |
US9524173B2 (en) | 2014-10-09 | 2016-12-20 | Brocade Communications Systems, Inc. | Fast reboot for a switch |
US9699029B2 (en) | 2014-10-10 | 2017-07-04 | Brocade Communications Systems, Inc. | Distributed configuration management in a switch group |
WO2016094555A1 (fr) | 2014-12-09 | 2016-06-16 | New York University | Protéines de fusion de neurotoxine clostridienne, fusions de propeptides, leur expression et leur utilisation |
ES2837699T3 (es) | 2014-12-19 | 2021-07-01 | Merz Pharma Gmbh & Co Kgaa | Medios y métodos para la determinación de la actividad biológica de BoNT/E en células |
US9628407B2 (en) | 2014-12-31 | 2017-04-18 | Brocade Communications Systems, Inc. | Multiple software versions in a switch group |
US9626255B2 (en) | 2014-12-31 | 2017-04-18 | Brocade Communications Systems, Inc. | Online restoration of a switch snapshot |
US9942097B2 (en) | 2015-01-05 | 2018-04-10 | Brocade Communications Systems LLC | Power management in a network of interconnected switches |
US10003552B2 (en) | 2015-01-05 | 2018-06-19 | Brocade Communications Systems, Llc. | Distributed bidirectional forwarding detection protocol (D-BFD) for cluster of interconnected switches |
DK3242884T3 (da) | 2015-01-09 | 2021-04-19 | Ipsen Bioinnovation Ltd | Kationiske neurotoksiner |
TWI704156B (zh) * | 2015-03-04 | 2020-09-11 | 德商曼茲法瑪股份有限公司 | 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法 |
US10038592B2 (en) | 2015-03-17 | 2018-07-31 | Brocade Communications Systems LLC | Identifier assignment to a new switch in a switch group |
US9807005B2 (en) | 2015-03-17 | 2017-10-31 | Brocade Communications Systems, Inc. | Multi-fabric manager |
US10579406B2 (en) | 2015-04-08 | 2020-03-03 | Avago Technologies International Sales Pte. Limited | Dynamic orchestration of overlay tunnels |
TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
US10439929B2 (en) | 2015-07-31 | 2019-10-08 | Avago Technologies International Sales Pte. Limited | Graceful recovery of a multicast-enabled switch |
US10704035B2 (en) * | 2015-08-27 | 2020-07-07 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
US10171303B2 (en) | 2015-09-16 | 2019-01-01 | Avago Technologies International Sales Pte. Limited | IP-based interconnection of switches with a logical chassis |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
US9912614B2 (en) | 2015-12-07 | 2018-03-06 | Brocade Communications Systems LLC | Interconnection of switches based on hierarchical overlay tunneling |
US11078472B2 (en) | 2016-01-20 | 2021-08-03 | Merz Pharma Gmbh & Co., Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
CA3010146A1 (fr) | 2016-03-02 | 2017-09-08 | Merz Pharma Gmbh & Co. Kgaa | Composition comprenant de la toxine botulique |
US11311633B2 (en) | 2016-04-16 | 2022-04-26 | University Of Florida Research Foundation, Incorporated | Satiation peptides for weight loss and altered taste sensitivity |
EP3263710A1 (fr) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production de neurotoxines clostridiales activées |
EP3504226A1 (fr) * | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Neurotoxine botulique manipulée |
EP3290437A1 (fr) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Nouvelles neurotoxines clostridiales recombinantes avec augmentation de la durée d'effet |
AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
EP3312193A1 (fr) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Nouvelles neurotoxines botuliques recombinantes à augmentation de la durée d'effet |
EP3333179A1 (fr) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Nouvelles toxines botuliques recombinantes à augmentation de la durée d'effet |
EP3335719A1 (fr) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Nouveau recombinant de neurotoxines botuliniques avec une chaîne légère stabilisée |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
EP3649143B1 (fr) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Nouvelles neurotoxines botuliques recombinantes présentant une durée d'effet accrue |
EP3700919A1 (fr) | 2017-10-26 | 2020-09-02 | Merz Pharma GmbH & Co. KGaA | Nouvelles neurotoxines botuliques recombinantes présentant une durée d'effet accrue |
US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
EP3723784A4 (fr) * | 2017-12-15 | 2022-01-12 | The Medical College of Wisconsin, Inc. | Utilisation de neurotoxines clostridiales modifiées en tant que vaccins et plates-formes de vaccins conjugués |
EP3728295A1 (fr) | 2017-12-20 | 2020-10-28 | Allergan, Inc. | Polypeptides du domaine de liaison cellulaire de toxine botulique et procédés d'utilisation pour des traitements de troubles associés à la fibrose |
WO2019243376A1 (fr) | 2018-06-18 | 2019-12-26 | Ipsen Biopharm Limited | Injection intramusculaire de toxine botulique pour le traitement de la vulvodynie |
EP3856923A1 (fr) | 2018-09-28 | 2021-08-04 | Ipsen Biopharm Limited | Essais de neurotoxine clostridiale à base de cellules |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
GB201907016D0 (en) | 2019-05-17 | 2019-07-03 | Ipsen Biopharm Ltd | Screening method to determine suitability for participation in a clinical trial |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
CN114957482A (zh) * | 2021-02-26 | 2022-08-30 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
EP4313120A1 (fr) | 2021-03-30 | 2024-02-07 | Ipsen Biopharm Limited | Traitement de troubles inflammatoires et de la douleur |
CN117396217A (zh) | 2021-03-30 | 2024-01-12 | 益普生生物制药有限公司 | 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗 |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
WO2023105289A1 (fr) | 2021-12-06 | 2023-06-15 | Dublin City University | Méthodes et compositions pour le traitement de la douleur |
CN118215495A (zh) * | 2022-04-01 | 2024-06-18 | 重庆誉颜制药有限公司 | 一种肉毒毒素蛋白组合物、制备方法及其应用 |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
CN116063535B (zh) * | 2022-09-14 | 2023-09-26 | 北京市疾病预防控制中心 | 一种抗体或其抗原结合片段及其制备方法和应用 |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
WO2024069191A1 (fr) | 2022-09-30 | 2024-04-04 | Ipsen Biopharm Limited | Neurotoxine clostridiale destinée à être utilisée dans un traitement de la cystite interstitielle |
GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007864A1 (fr) * | 1996-08-23 | 1998-02-26 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Fragments de toxines recombines |
US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5919665A (en) † | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
AU1350792A (en) * | 1991-01-16 | 1992-08-27 | General Hospital Corporation, The | Human galanin |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
EP0760681B1 (fr) | 1994-05-31 | 1999-09-01 | Allergan, Inc | Modification de toxines de clostridium utilisees comme proteines de transport |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
AU4245097A (en) | 1996-08-28 | 1998-03-19 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for (clostridium botulinum) neurotoxin |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
WO1999055359A1 (fr) | 1998-04-29 | 1999-11-04 | Allergan Sales, Inc. | Compositions et procedes permettant d'etendre l'action d'une neurotoxine clostridiale |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
WO2000023427A1 (fr) | 1998-10-20 | 2000-04-27 | Basf Aktiengesellschaft | Procede de production de 1-methyl-6-halogenoalkyluracyles eventuellement substitues |
US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
EP2267010B1 (fr) | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Neurotoxines recombinantes activables |
US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
US6641820B1 (en) * | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6500436B2 (en) * | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
MXPA04006572A (es) | 2002-01-10 | 2005-11-04 | Upjohn Co | Terapia de combinacion antivirica. |
GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US20060024331A1 (en) | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
PL1830872T3 (pl) * | 2004-12-01 | 2011-09-30 | Sec Dep For Health | Białka fuzyjne |
CA2588292C (fr) | 2004-12-01 | 2019-01-15 | Health Protection Agency | Conjugues proteiques non cytotoxiques |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
JP2008532549A (ja) * | 2005-03-15 | 2008-08-21 | アラーガン、インコーポレイテッド | 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素 |
-
2000
- 2000-08-25 EP EP10185389.3A patent/EP2267010B1/fr not_active Expired - Lifetime
- 2000-08-25 WO PCT/US2000/023427 patent/WO2001014570A1/fr active IP Right Grant
- 2000-08-25 KR KR1020027002270A patent/KR100876060B1/ko not_active IP Right Cessation
- 2000-08-25 CA CA002380457A patent/CA2380457A1/fr not_active Abandoned
- 2000-08-25 CN CNB008120099A patent/CN1214114C/zh not_active Expired - Lifetime
- 2000-08-25 DE DE60032367T patent/DE60032367T3/de not_active Expired - Lifetime
- 2000-08-25 AT AT00964920T patent/ATE348178T1/de not_active IP Right Cessation
- 2000-08-25 ES ES00964920T patent/ES2277854T5/es not_active Expired - Lifetime
- 2000-08-25 JP JP2001518882A patent/JP2003507073A/ja active Pending
- 2000-08-25 AU AU75731/00A patent/AU777556B2/en not_active Expired
- 2000-08-25 US US09/648,692 patent/US7132259B1/en not_active Expired - Lifetime
- 2000-08-25 EP EP10185391A patent/EP2264052A3/fr not_active Withdrawn
- 2000-08-25 BR BR0012759-0A patent/BR0012759A/pt not_active Application Discontinuation
- 2000-08-25 EP EP10185355.4A patent/EP2267008B1/fr not_active Expired - Lifetime
- 2000-08-25 EP EP06002253.0A patent/EP1700918B1/fr not_active Expired - Lifetime
- 2000-08-25 EP EP00964920A patent/EP1206554B2/fr not_active Expired - Lifetime
- 2000-08-25 EP EP10185370.3A patent/EP2267009B1/fr not_active Expired - Lifetime
-
2002
- 2002-10-18 HK HK02107594.3A patent/HK1046020B/zh not_active IP Right Cessation
-
2006
- 2006-01-05 US US11/326,265 patent/US7419676B2/en not_active Expired - Lifetime
- 2006-12-13 US US11/610,440 patent/US7422877B2/en not_active Expired - Lifetime
-
2007
- 2007-07-24 US US11/782,112 patent/US7709228B2/en not_active Expired - Fee Related
- 2007-08-27 US US11/845,252 patent/US7897157B2/en not_active Expired - Fee Related
- 2007-08-27 US US11/845,167 patent/US7749514B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/926,812 patent/US20080182294A1/en not_active Abandoned
-
2008
- 2008-07-22 US US12/177,415 patent/US8211671B2/en not_active Expired - Lifetime
- 2008-07-30 US US12/182,801 patent/US7959933B2/en not_active Expired - Fee Related
- 2008-08-15 US US12/192,546 patent/US8071110B2/en not_active Expired - Fee Related
- 2008-08-15 US US12/192,900 patent/US8273358B2/en not_active Expired - Lifetime
- 2008-08-15 US US12/192,419 patent/US20090005313A1/en not_active Abandoned
- 2008-08-18 US US12/193,527 patent/US7985411B2/en not_active Expired - Fee Related
- 2008-08-21 US US12/195,985 patent/US20090030188A1/en not_active Abandoned
- 2008-08-22 US US12/196,658 patent/US8003351B2/en not_active Expired - Fee Related
- 2008-08-22 US US12/196,381 patent/US8119370B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007864A1 (fr) * | 1996-08-23 | 1998-02-26 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Fragments de toxines recombines |
US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2267009A3 (fr) | Neurotoxines recombinantes activables | |
WO2001053312A8 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2001053455A3 (fr) | Nouveaux acides nucleiques et polypeptides associes | |
WO2001075067A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2001057188A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2002022660A3 (fr) | Noveaux acides nucleiques et polypeptides | |
WO2001066689A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2002031111A3 (fr) | Acides nucleiques et polypeptides | |
WO2000023472A3 (fr) | Proteines de fusion a interferon beta et leurs utilisations | |
WO2004009834A3 (fr) | Nouveaux acides nucleiques et polypeptides secretes | |
WO2001088088A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
EP1508574A3 (fr) | Protéines fluorescentes à grande longueur d'onde génétiquement modifiées | |
WO2003054152A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2003025148A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2003023013A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2002081731A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2002059260A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
EP2270148A3 (fr) | Méthode de régulation de l'activité d'une molécule immunologiquement fonctionnelle | |
WO2003029271A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2002018424A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
IL184227A0 (en) | Biologically active peptides | |
WO2001079449A3 (fr) | Acides nucleiques et polypeptides nouveaux | |
WO2003080795A8 (fr) | Nouveaux acides nucléiques et polypeptides sécrétés | |
WO2002044340A3 (fr) | Nouveaux acides nucleiques et polypeptides | |
WO2001053453A8 (fr) | Nouveaux acides nucleiques de moelle osseuse et polypeptides associes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1206554 Country of ref document: EP Kind code of ref document: P Ref document number: 1700918 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LI, YAN Inventor name: DOLLY, J. OLIVER Inventor name: CHAN, CHION KUO |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/70 20060101ALI20110315BHEP Ipc: C12N 9/52 20060101ALI20110315BHEP Ipc: C07K 19/00 20060101ALI20110315BHEP Ipc: C12N 15/57 20060101ALI20110315BHEP Ipc: C12N 15/62 20060101AFI20110315BHEP |
|
17P | Request for examination filed |
Effective date: 20110928 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
17Q | First examination report despatched |
Effective date: 20120327 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 60048766 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07K0014330000 Ipc: C12N0015620000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/33 20060101ALI20140602BHEP Ipc: C12N 9/52 20060101ALI20140602BHEP Ipc: C12N 15/70 20060101ALI20140602BHEP Ipc: C12N 15/57 20060101ALI20140602BHEP Ipc: C12N 15/62 20060101AFI20140602BHEP Ipc: C07K 19/00 20060101ALI20140602BHEP |
|
INTG | Intention to grant announced |
Effective date: 20140619 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DOLLY, J. OLIVER Inventor name: LI, YAN Inventor name: CHAN, CHION KUO |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1206554 Country of ref document: EP Kind code of ref document: P Ref document number: 1700918 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 693631 Country of ref document: AT Kind code of ref document: T Effective date: 20141115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 60048766 Country of ref document: DE Effective date: 20141211 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 693631 Country of ref document: AT Kind code of ref document: T Effective date: 20141029 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20141029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150302 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150130 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60048766 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20150730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150825 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160429 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150825 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150825 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141029 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20190828 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60048766 Country of ref document: DE |